Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm Metastasis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16 Ovarian Neoplasms 6 Neoplasms 6 Colorectal Neoplasms 4 Recurrence 3 Prostatic Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Radiation Pneumonitis 2 Peritoneal Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Ovarian Diseases 1 Oligodendroglioma 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Mesothelioma 1 Melanoma, Cutaneous Malignant 1 Malignant Solid Tumour 1

Interventions

pembrolizumab 128 Gemcitabine 115 Capecitabine 107 Fluorouracil 99 Paclitaxel 98 Bevacizumab 91 Oxaliplatin 89 Nivolumab 84 Leucovorin 81 Docetaxel 77 Radiosurgery 74 Irinotecan 72 Cisplatin 69 Carboplatin 69 Cyclophosphamide 60 Magnetic Resonance Spectroscopy 59 Cetuximab 59 Biopsy 51 Specimen Handling 50 Trastuzumab 46 Radiotherapy 44 Ipilimumab 43 Pemetrexed 38 Everolimus 38 Drug Therapy 38 Albumin-Bound Paclitaxel 36 130-nm albumin-bound paclitaxel 36 Fulvestrant 34 Doxorubicin 34 aldesleukin 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡